PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer

<p dir="ltr">Protein Kinase D1 (PKD1) is a serine/threonine kinase encoded by the <i>PRKD1</i> gene. PKD1 has been previously shown to be a prognostic factor in ERα+ tamoxifen-resistant breast tumors and PKD1 overexpression confers estrogen independence to ERα+ MCF7 cells...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Caroline Spasojevic (3619418) (author)
مؤلفون آخرون: Elisabetta Marangoni (655592) (author), Sophie Vacher (233965) (author), Franck Assayag (3157383) (author), Didier Meseure (666209) (author), Sophie Château-Joubert (11410163) (author), Martine Humbert (252271) (author), Manale Karam (3619412) (author), Jean Marc Ricort (18696934) (author), Christian Auclair (140039) (author), Marie Regairaz (1465762) (author), Ivan Bièche (3492) (author)
منشور في: 2018
الموضوعات:
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
الوصف
الملخص:<p dir="ltr">Protein Kinase D1 (PKD1) is a serine/threonine kinase encoded by the <i>PRKD1</i> gene. PKD1 has been previously shown to be a prognostic factor in ERα+ tamoxifen-resistant breast tumors and PKD1 overexpression confers estrogen independence to ERα+ MCF7 cells. In the present study, our goal was to determine whether PKD1 is a prognostic factor and/or a relevant therapeutic target in breast cancer. We analyzed <i>PRKD1</i> mRNA levels in 527 primary breast tumors. We found that high <i>PRKD1</i> mRNA levels were significantly and independently associated with a low metastasis-free survival in the whole breast cancer population and in the triple-negative breast cancer (TNBC) subtype specifically. High <i>PRKD1</i> mRNA levels were also associated with a low overall survival in TNBC. We identified novel PKD1 inhibitors and assessed their antitumor activity <i>in vitro</i> in TNBC cell lines and <i>in vivo</i> in a TNBC patient-derived xenograft (PDX) model. Pharmacological inhibition and siRNA-mediated depletion of PKD1 reduced colony formation in MDA-MB-436 TNBC cells. PKD1 inhibition also reduced tumor growth <i>in vivo</i> in a TNBC PDX model. Together, these results establish PKD1 as a poor prognostic factor and a potential therapeutic target in TNBC.</p><h2>Other Information</h2><p dir="ltr">Published in: Oncotarget<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.18632/oncotarget.25292" target="_blank">https://dx.doi.org/10.18632/oncotarget.25292</a></p>